-+ 0.00%
-+ 0.00%
-+ 0.00%

Roche's Vabysmo Lifts Vision By 4.6 Letters In Untreated nAMD Eyes And 8.2 In DME After 12 Months In Real-World VOYAGER Data Presented At EURETINA

Benzinga·10/01/2026 07:28:21
Listen to the news
  • New real-world results for Vabysmo in nAMD, DME and RVO reinforce robust effectiveness and durability across previously untreated and treated eyes, with no new safety signals1-3
  • Advanced AI-enabled analysis of imaging confirms rapid and meaningful anatomical drying supporting Vabysmo as a standard-of-care therapy in routine clinical care4,5
  • With more than 5,000 patients enrolled, VOYAGER is the largest, prospective, non-interventional real-world dataset evaluating Vabysmo across diverse clinical practice settings worldwide1-3